文献速递结核与非结核分枝杆菌

每周3HP方案对比每日4RIF方案治疗结核感染的随机对照试验

Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该多中心开放标签随机对照试验在澳大利亚悉尼7家结核病诊所纳入210例结核感染参与者,比较每周3HP方案与每日4RIF方案的治疗完成率。结果显示3HP组完成率84.9%显著高于4RIF组65.4%(RR 1.30,95%CI 1.22-1.38,P<.001),两组不良事件发生率相似,无治疗相关死亡。

要点

  • 每周3HP联合短信提醒的治疗完成率显著优于每日4RIF(84.9% vs 65.4%)。
  • 两组任何级别不良事件发生率相似(24.5% vs 20.2%),无治疗相关死亡。
  • 结果支持更广泛实施3HP方案以优化结核感染治疗的依从性和结局。

核心结论

  • 每周3HP联合短信提醒的治疗完成率显著高于每日4RIF,安全性相似,支持更广泛实施3HP方案。

研究设计与样本

  • 多中心、开放标签、平行组随机对照试验,2019年7月至2024年6月在澳大利亚悉尼7家结核病诊所开展。
  • 纳入任何年龄的结核感染参与者210例,按1:1随机分组并分层,3HP组106例、4RIF组104例,所有剂量自行服用。
  • 3HP组接受每周短信依从性提醒,两组均接受标准诊所随访,主要结局为治疗完成(服入≥90%处方剂量),按意向性分析。

主要发现

  • 3HP组治疗完成率84.9%,4RIF组65.4%,相对危险度1.30(95%CI 1.22-1.38),P<.001。
  • 任何级别不良事件发生率3HP组24.5%、4RIF组20.2%,未报告治疗相关死亡。

关键数值与推荐

  • 治疗完成定义为服入≥90%处方剂量。
  • 3HP组完成率84.9%,4RIF组65.4%,RR 1.30(95%CI 1.22-1.38),P<.001。
  • 任何级别不良事件:3HP组24.5%,4RIF组20.2%。

临床怎么用

  • 在结核感染治疗中可优先考虑每周3HP方案并辅以短信提醒以提高治疗完成率。
  • 3HP与4RIF安全性相似,选择方案时可结合依从性支持措施综合决策。

局限性

  • 开放标签设计可能影响结局评估。
  • 研究在澳大利亚悉尼7家结核病诊所开展,外推至其他地区需谨慎。
  • 3HP组接受短信提醒而4RIF组未接受,依从性支持措施不对等可能影响完成率比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of tuberculosis infection (TBI) is a key pillar of the World Health Organization End TB Strategy. Two short-course rifamycin-based regimens-3 months of weekly isoniazid plus rifapentine (3HP) and 4 months of daily rifampicin (4RIF)-are widely recommended; however, they have not previously been directly compared in a randomized controlled trial. We compared treatment completion between 3HP and 4RIF among individuals with TBI. METHODS: We conducted a multicenter, open-label, parallel-group randomized controlled trial across 7 tuberculosis clinics in Sydney, Australia, between July 2019 and June 2024. Participants of any age with TBI were randomized 1:1, stratified by site, to receive either weekly 3HP or daily 4RIF. All doses were self-administered. Participants in the 3HP group received weekly Short Message Service (SMS) adherence reminders; both groups received standard clinic follow-up. The primary outcome was treatment completion, defined as ingestion of ≥90% of prescribed doses. Analyses were conducted on an intention-to-treat basis. RESULTS: A total of 210 participants were enrolled (106 assigned to 3HP and 104 to 4RIF). Treatment completion was significantly higher in the 3HP group (84.9%) than in the 4RIF group (65.4%; relative risk, 1.30 [95% confidence interval, 1.22-1.38]; P < .001). Adverse events of any grade occurred in 24.5% of participants receiving 3HP and 20.2% receiving 4RIF. No treatment-related deaths were reported. CONCLUSIONS: Weekly 3HP supported by SMS reminders achieved significantly higher treatment completion than daily 4RIF, with similar safety. These findings support broader implementation of 3HP to optimize adherence and outcomes in TBI treatment programs. CLINICAL TRIALS REGISTRATION: Australian New Zealand Clinical Trials Registry (ACTRN12618001672246).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chang VWL, Li Q, Barnes D, et al. Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial. Clin Infect Dis. 2026. PMID: 42136397. doi:10.1093/cid/ciag306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。